香港股市 將在 6 小時 34 分鐘 開市
  • 恒指

    17,297.94
    -275.64 (-1.57%)
     
  • 國指

    5,872.38
    -98.72 (-1.65%)
     
  • 上證綜指

    3,078.55
    -23.14 (-0.75%)
     
  • 道指

    33,924.28
    -422.75 (-1.23%)
     
  • 標普 500

    3,973.27
    -52.85 (-1.31%)
     
  • 納指

    11,086.22
    -140.13 (-1.25%)
     
  • Vix指數

    21.87
    +1.37 (+6.68%)
     
  • 富時100

    7,474.02
    -12.65 (-0.17%)
     
  • 紐約期油

    77.25
    +0.97 (+1.27%)
     
  • 金價

    1,740.40
    -13.60 (-0.78%)
     
  • 美元

    7.8161
    +0.0031 (+0.04%)
     
  • 人民幣

    0.9216
    +0.0051 (+0.56%)
     
  • 日圓

    0.0560
    +0.0001 (+0.16%)
     
  • 歐元

    8.0976
    -0.0256 (-0.31%)
     
  • Bitcoin

    16,193.09
    -360.16 (-2.18%)
     
  • CMC Crypto 200

    380.02
    -0.27 (-0.07%)
     

HUTCHMED Cancer Med Cuts Death Risk By 34% In Metastatic Colorectal Cancer

  • HUTCHMED (China) Limited (NASDAQ: HCMannounced summary results of the 691-patient trial of fruquintinib. These results have been shared in an abstract of the upcoming presentation at the European Society for Medical Oncology Congress 2022.

  • The MRCT FRESCO-2 study demonstrated that treatment with fruquintinib resulted in a statistically significant and clinically meaningful increase in the primary overall survival (OS) endpoint and key secondary progression-free survival (PFS) endpoint compared to treatment with placebo.

  • The median OS was 7.4 months for the 461 patients treated with fruquintinib compared to 4.8 months for the 230 patients in the placebo group.

  • Median PFS was 3.7 months for patients treated with fruquintinib compared to 1.8 months for patients in the placebo group.

  • The disease control rate was 55.5% in the fruquintinib group compared to 16.1% for patients in the placebo group.

  • The safety profile of fruquintinib in FRESCO-2 was consistent with previously reported fruquintinib studies.

  • Price Action: HCM shares are trading 4.74% higher at 13.03 on the last check Thursday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.